Eli Lilly received FDA approval for Imlunestrant (Inluriyo), an oral selective estrogen receptor degrader, to treat adults with advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer harboring ESR1 mutations. This second-line therapy demonstrated a 38% reduction in disease progression or death risk compared to standard endocrine treatments, with manageable side effects. This approval advances the oral SERD class in breast cancer management, offering a less invasive alternative to injectable agents.